The pharmacogenetics of antiretroviral therapy

Purpose of reviewAlthough the past 20 years have seen many advances in HIV pharmacotherapy, host variability has only been more recently recognized as an important driver of both treatment response and toxicity. This review will focus on the importance of variability in drug metabolizing enzymes and the potential research and clinical applications of these findings in HIV care. Recent findingsThe treatment of HIV is complex and involves chronic treatment with multiple drugs and drug classes. Recent research has been important in uncovering genetic differences in drug metabolizing and drug transporter genes, which underpin dose-dependent toxicity and efficacy, but also in genes defining differences in immune response and human leukocyte antigen genes, which restrict processes that are less dependent on the drug dose. SummaryThe advancement of pharmacogenetics will continue to further our knowledge of disease–drug interactions and pathogenesis. Ultimately, the goals of pharmacogenetics and pharmacogenomics in HIV medicine will be the development of the right drugs for the right patient or population. The strong association between HLA-B*5701 and abacavir hypersensitivity reaction shows promise for a genetic screening test to be feasibly incorporated into clinical practice. The clinical applicability of many findings demonstrating associations between single nucleotide polymorphisms, particularly in drug metabolism and transporter genes and drug efficacy and toxicity, are currently uncertain.

[1]  S. Mallal,et al.  Efavirenz and CYP2B6 polymorphism: implications for drug toxicity and resistance. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  K. Tashima,et al.  Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  R. V. van Schaik,et al.  Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism. , 2006, British journal of clinical pharmacology.

[4]  M. Schumacher,et al.  A marker for Stevens-Johnson syndrome …: ethnicity matters , 2006, The Pharmacogenomics Journal.

[5]  V. Soriano,et al.  Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C-->T polymorphism at the multidrug resistance gene 1. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  G. Peytavin,et al.  Absence of association between MDR1 genetic polymorphisms, indinavir pharmacokinetics and response to highly active antiretroviral therapy , 2005, AIDS.

[7]  M. Eichelbaum,et al.  Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz , 2005, Pharmacogenetics and genomics.

[8]  M. Hirsch,et al.  Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study. , 2005, The Journal of infectious diseases.

[9]  K. Tashima,et al.  Impact of Efavirenz on Neuropsychological Performance and Symptoms in HIV-Infected Individuals , 2005, Annals of Internal Medicine.

[10]  Amalio Telenti,et al.  Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia. , 2005, The Journal of infectious diseases.

[11]  S. Khoo,et al.  Efavirenz detectable in plasma 8 weeks after stopping therapy and subsequent development of non-nucleoside reverse transcriptase inhibitor-associated resistance. , 2005, AIDS.

[12]  Marshall Summar,et al.  Mitochondrial haplogroups and peripheral neuropathy during antiretroviral therapy: an adult AIDS clinical trials group study , 2005, AIDS.

[13]  R. Kim,et al.  Transporters and drug therapy: Implications for drug disposition and disease , 2005, Clinical pharmacology and therapeutics.

[14]  A. Telenti,et al.  Influence of ABCB1, ABCC1, ABCC2, and ABCG2 haplotypes on the cellular exposure of nelfinavir in vivo , 2005, Pharmacogenetics & Genomics.

[15]  Jürgen Brockmöller,et al.  Pharmacogenetics-based therapeutic recommendations — ready for clinical practice? , 2005, Nature Reviews Drug Discovery.

[16]  M. Caldwell,et al.  A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data. , 2005, Clinical medicine & research.

[17]  S. Mallal,et al.  Clinical and immunogenetic correlates of abacavir hypersensitivity , 2005, AIDS.

[18]  A. Owen,et al.  The implications of P‐glycoprotein in HIV: friend or foe? , 2005, Fundamental & clinical pharmacology.

[19]  S. Mallal,et al.  HLA-B*5701 typing by sequence-specific amplification: validation and comparison with sequence-based typing. , 2005, Tissue antigens.

[20]  G. Wilkinson,et al.  Drug metabolism and variability among patients in drug response. , 2005, The New England journal of medicine.

[21]  F. van Leth,et al.  Are Adverse Events of Nevirapine and Efavirenz Related to Plasma Concentrations? , 2005, Antiviral therapy.

[22]  A. Telenti,et al.  Modeling the influence of APOC3, APOE, and TNF polymorphisms on the risk of antiretroviral therapy-associated lipid disorders. , 2005, The Journal of infectious diseases.

[23]  V. Soriano,et al.  Influence of 516G>T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  Yuan-Tsong Chen,et al.  HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[25]  S. Spector,et al.  An MDR1-3435 variant is associated with higher plasma nelfinavir levels and more rapid virologic response in HIV-1 infected children , 2005, AIDS.

[26]  C. Moore,et al.  Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts , 2005, AIDS.

[27]  Sien‐Sing Yang,et al.  Genetic factors related to unconjugated hyperbilirubinemia amongst adults , 2005, Pharmacogenetics and genomics.

[28]  Amalio Telenti,et al.  Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients , 2005, Pharmacogenetics and genomics.

[29]  Catia Marzolini,et al.  Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study , 2004, AIDS.

[30]  D. Margolis,et al.  Atazanavir for the Treatment of Human Immunodeficiency Virus Infection , 2004, Pharmacotherapy.

[31]  S. Mallal,et al.  Pharmacogenetics of antiretroviral therapy: genetic variation of response and toxicity. , 2004, Pharmacogenomics.

[32]  W. Sugiura,et al.  Influence of Single-Nucleotide Polymorphisms in the Multidrug Resistance-1 Gene on the Cellular Export of Nelfinavir and Its Clinical Implication for Highly Active Antiretroviral Therapy , 2004, Antiviral therapy.

[33]  S. Oka,et al.  Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens. , 2004, Biochemical and biophysical research communications.

[34]  M. Pirmohamed,et al.  Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity. , 2004, Pharmacogenetics.

[35]  P. Jolliet,et al.  No relationship between high nevirapine plasma concentration and hepatotoxicity in HIV-1-infected patients naive of antiretroviral treatment or switched from protease inhibitors , 2004, European Journal of Clinical Pharmacology.

[36]  S. Mallal,et al.  The role of nucleoside reverse transcriptase inhibitors in the fat redistribution syndrome. , 2004, Journal of HIV therapy.

[37]  I. James,et al.  Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[38]  D. Dieterich,et al.  Drug-induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[39]  S. Belknap,et al.  Serious Adverse Cutaneous and Hepatic Toxicities Associated With Nevirapine Use by Non–HIV-Infected Individuals , 2004, Journal of acquired immune deficiency syndromes.

[40]  J. Schubert,et al.  No influence of the P-glycoprotein genotype (MDR1 C3435T) on plasma levels of lopinavir and efavirenz during antiretroviral treatment. , 2003, European journal of medical research.

[41]  D. Mayers,et al.  A Comprehensive Hepatic Safety Analysis of Nevirapine in Different Populations of HIV Infected Patients* , 2003, Journal of acquired immune deficiency syndromes.

[42]  M. Abu-Asab,et al.  Characterization of a potential animal model of an idiosyncratic drug reaction: nevirapine-induced skin rash in the rat. , 2003, Chemical research in toxicology.

[43]  C. Bellodi,et al.  MDR1 C3435T genetic polymorphism does not influence the response to antiretroviral therapy in drug-naive HIV-positive patients , 2003, AIDS.

[44]  P. Harrigan,et al.  Influence of polymorphisms within the CX3CR1 and MDR-1 genes on initial antiretroviral therapy response , 2003, AIDS.

[45]  C. Moore,et al.  Tumour necrosis factor-alpha gene -238G/A promoter polymorphism associated with a more rapid onset of lipodystrophy , 2003, AIDS.

[46]  E. Schuetz,et al.  Genetic contribution to variable human CYP3A-mediated metabolism. , 2002, Advanced drug delivery reviews.

[47]  M. Clerici,et al.  Thymic volume predicts long-term immune reconstitution in HIV-infected children treated with highly active antiretroviral therapy , 2002 .

[48]  M. Pirmohamed,et al.  TNF-α promoter region gene polymorphisms in HIV-positive patients with lipodystrophy , 2002 .

[49]  S. Hetherington,et al.  Risk factor analysis of hypersensitivity reactions to abacavir. , 2002, Clinical therapeutics.

[50]  Clive E. Bowman,et al.  Genetic variations in HLA-B region and hypersensitivity reactions to abacavir , 2002, The Lancet.

[51]  C. Moore,et al.  Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir , 2002, The Lancet.

[52]  Jacques Fellay,et al.  Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study , 2002, The Lancet.

[53]  J. Ruidavets,et al.  An interaction between apo C-III variants and protease inhibitors contributes to high triglyceride/low HDL levels in treated HIV patients , 2001, AIDS.

[54]  J. Hudson,et al.  The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants. , 2001, Pharmacogenetics.

[55]  P. Demoly,et al.  Hypersensitivity Related to Abacavir in Two Members of a Family , 2001, The Annals of pharmacotherapy.

[56]  E. Hawe,et al.  Apolipoprotein E4 and coronary heart disease in middle-aged men who smoke: a prospective study , 2001, The Lancet.

[57]  U. Hofmann,et al.  Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. , 2001, Pharmacogenetics.

[58]  Y. Hekster,et al.  Analysis of variation in plasma concentrations of nelfinavir and its active metabolite M8 in HIV-positive patients , 2001, AIDS.

[59]  R. Green,et al.  Mechanism of indinavir-induced hyperbilirubinemia. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[60]  A. Telenti,et al.  Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients , 2001, AIDS.

[61]  D. Bulman,et al.  Single and multiple dose pharmacokinetics of nelfinavir and CYP2C19 activity in human immunodeficiency virus-infected patients with chronic liver disease. , 2000, British journal of clinical pharmacology.

[62]  R H Levy,et al.  Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[63]  A. Mutlib,et al.  Identification and characterization of efavirenz metabolites by liquid chromatography/mass spectrometry and high field NMR: species differences in the metabolism of efavirenz. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[64]  I. Pastan,et al.  HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. , 1998, Biochemistry.

[65]  J. Breslow,et al.  Common genetic variation in the promoter of the human apo CIII gene abolishes regulation by insulin and may contribute to hypertriglyceridemia. , 1995, The Journal of clinical investigation.

[66]  W. Kalow,et al.  Ethnic Differences in Drug Metabolism , 1982, Clinical pharmacokinetics.

[67]  H. Lehmann,et al.  The familial incidence of low pseudocholinesterase level. , 1956, Lancet.

[68]  B. Shastry,et al.  Pharmacogenetics and the concept of individualized medicine , 2006, The Pharmacogenomics Journal.

[69]  B. Thiers.  HLA-B*5801 Allele as a Genetic Marker for Severe Cutaneous Adverse Reactions Caused by Allopurinol , 2006 .

[70]  V. Soriano,et al.  Influence of 516 G 1 T Polymorphisms at the Gene Encoding the CYP 450-2 B 6 Isoenzyme on Efavirenz Plasma Concentrations in HIV-Infected Subjects , 2005 .

[71]  A. Mrhar,et al.  Influence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance dose , 2005, The Pharmacogenomics Journal.

[72]  R. Hartkoorn.  Relevance of Drug Transporters and Drug Metabolism Enzymes to Nevirapine: Superimposition of Host Genotype , 2005 .

[73]  S. Mallal,et al.  Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV Cohort , 2005 .

[74]  Yuan-Tsong Chen,et al.  A marker for Stevens–Johnson syndrome , 2004 .

[75]  M. Pirmohamed,et al.  TNF-alpha promoter region gene polymorphisms in HIV-positive patients with lipodystrophy. , 2002, AIDS.

[76]  E. Schuetz,et al.  G enetic contribution to variable human CYP 3 A-mediated metabolism , 2002 .

[77]  E. Phillips,et al.  The chronicles of HIV therapeutics: where to begin, when to start and how will it end--a tale of two decades and beyond? , 2002, The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique.

[78]  C. Moore,et al.  HLA-DQ 3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir , 2022 .

[79]  J. Schubert,et al.  Annals of Clinical Microbiology and Antimicrobials No Influence of the P-glycoprotein Polymorphisms Mdr1 G2677t/a and C3435t on the Virological and Immunological Response in Treatment Naïve Hiv-positive Patients , 2022 .